Please assess the completion status of the following clinical trial:

Trial Title: Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who have volunteered and consented to participate in the study.~2. Subjects who have no contraindication to taking high dose, oral prednisone or Acthar.~3. Male or Female subjects age 18 or greater years of age.~4. Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) based on 2010 McDonald Criteria.~5. Subjects without an active infection (Note: If a patient is found to have an uncomplicated UTI and agrees to start on appropriate antibiotic treatment, they can continue in the study).~6. Subjects who are experiencing a protocol defined MS relapse within two weeks of relapse onset.~7. Subjects who are able and willing to sign a consent form.~Exclusion Criteria:~1. Subjects who are less than 18 years of age.~2. Subjects with any contraindication to taking Acthar.~3. Subjects with an active infection other than an uncomplicated urinary tract infection (UTI) (subjects determined to have a UTI who agree to be treated with appropriate antibiotics will not be excluded).~4. Subjects with an immune deficiency.~5. Subjects with a history of any of the following conditions: gastrointestinal ulcers, diabetes mellitus, gestational diabetes, malignant hypertension or steroid induced psychosis.~6. Subjects who are pregnant or breastfeeding.~7. Subjects who are unable or unwilling to sign consent form.~8. Patient is unable or unwilling to participate in phone and clinic follow up.~9. Other factors that in the opinion of the Principal Investigator would exclude the subject from participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single arm (Type: EXPERIMENTAL): Acthar 80 units subcutaneously for five consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).